Livingstone Health Holdings Limited: FY2026 Financial Review and Investment Analysis
Livingstone Health Holdings Limited (“Livingstone Health”) released its unaudited condensed interim financial statements for the six months and full year ended 31 March 2026. The Group operates a network of specialist and primary healthcare, as well as related healthcare businesses in Singapore. This article provides an in-depth analysis of its key financial metrics, operational highlights, and investment implications based strictly on the disclosed report.
Key Financial Metrics and Performance Table
| Metric | 2H FY2026 (6M Ended Mar 2026) |
1H FY2026 (6M Ended Sep 2025) |
2H FY2025 (6M Ended Mar 2025) |
YoY Change | QoQ Change |
|---|---|---|---|---|---|
| Revenue (S\$’000) | 14,468 | 14,820 | 14,195 | +1.9% | -2.4% |
| Net (Loss)/Profit After Tax (S\$’000) | (531) | 35 | 87 | NM* | NM* |
| EPS (Cents, Basic) | 0.00 | 0.04 | 0.07 | NM* | NM* |
| Net Asset Value/Share (cents) | 1.10 (as at Mar 2026) | – | 1.04 (as at Mar 2025) | +5.8% | – |
| Dividend (per share) | Nil | Nil | Nil | – | – |
*NM: Not meaningful due to net loss, not profit.
Historical Performance and Trends
- Revenue: For FY2026, revenue increased by 5.9% YoY to S\$29.3 million, driven by growth across all business segments—Specialist Healthcare (+2.9%), Primary Healthcare (+7.1%), and Others (+19.3%).
- Profitability: Net profit attributable to owners fell sharply from S\$0.6 million in FY2025 to S\$0.2 million in FY2026. Excluding one-off losses and shutdown costs from the Ardennes business, adjusted net profit would have been S\$0.6 million.
- Margins and Expenses: Medical supplies and employee expenses rose in line with revenue and team expansion. Other operating expenses increased due to higher marketing and rental costs, and one-off asset disposal losses related to the Ardennes closure. Finance costs declined as borrowings and lease liabilities reduced.
- EPS & NAV: Basic EPS dropped from S\$0.10 to S\$0.04, reflecting lower profitability. Net asset value per share improved marginally, from 1.04 to 1.10 cents.
Exceptional Items and Corporate Actions
- Closure of Ardennes Healthcare: The underperforming Ardennes health screening centre was closed in February 2026, incurring non-recurring losses and asset write-offs.
- Acquisitions: The Group completed the acquisition of a 100% stake in PMG INT 2 Pte Ltd (renamed PMG RH Pte Ltd) and Wellington Pte Ltd, adding goodwill of S\$1.4 million and expanding its network of primary clinics.
- Divestments & Striking-Off: Two dormant subsidiaries (Venture Investment Pte Ltd and Atlas Physiotherapy Pte Ltd) were struck off. A 2% stake in VirtueMed Pte. Ltd. was divested, and the company was de-consolidated.
- Fundraising: The Group raised S\$1.38 million via Rights cum Warrants Issue in July 2024, and S\$19,000 via the exercise of warrants in FY2026. Additional banking facilities of S\$4.0 million were secured to support expansion and working capital.
- Related-Party Transactions: Lease payments of S\$251,000 were made to a company controlled by the family of a director, at market rates. Other related-party transactions were minor and disclosed in full.
Dividend Policy
- No dividend was declared or recommended for FY2026 or the prior year. The Board cited the need to conserve cash for working capital and future expansion.
Management Commentary and Outlook
The report does not contain a separate Chairman’s Statement, but management commentary is included in the review section:
“During the year, the Group closed the underperforming Ardennes health screening centre, as part of the Group’s strategic decision in rationalising its operations while optimising its healthcare network, to further improve its operational efficiency. The Group will continue to invest in and focus on retaining its medical doctors and healthcare talent base, which has been instrumental in sustaining the Group’s revenue growth. … The Group remains cautious of the business outlook as the operating environment continues to be challenging with rising business costs.”
The tone is pragmatic and cautious, highlighting ongoing investments in talent and network expansion, but warning of macroeconomic headwinds and inflationary pressures.
Forecasted Events and Risks
- The Group plans further network expansion, leveraging new banking facilities to pursue acquisition opportunities.
- Management cites a challenging operating environment due to inflation and geopolitical risks, suggesting that profit growth may remain modest in the near term.
Conclusion and Investment Recommendation
Overall Assessment: Livingstone Health delivered moderate revenue growth and maintained a stable asset base, but profitability remains weak due to restructuring costs and rising business expenses. The group’s strategy is to consolidate and expand its healthcare platform, but macroeconomic challenges and cost pressures are likely to limit immediate earnings recovery.
- If you are a current shareholder: Consider holding. The company is investing in long-term growth and operational efficiency, and its balance sheet remains healthy. However, the absence of dividends and slow profit growth mean patience is required. Monitor for signs of improved profitability and successful execution of expansion plans.
- If you are not holding the stock: Wait. There is no immediate catalyst for strong share price appreciation or dividend yield. Entry may be more attractive once there is evidence of sustained profitability or clearer benefits from recent acquisitions.
Disclaimer: This analysis is based solely on the company’s published report and does not constitute investment advice. Investors should consider their own risk profile and consult a licensed financial advisor before making any investment decisions.
利文斯通医疗控股有限公司：2026财年财报分析与投资建议
利文斯通医疗控股有限公司（“利文斯通医疗”）公布了截至2026年3月31日的六个月及全年未经审计的中期财务报表。集团在新加坡运营专科和初级医疗网络及相关医疗业务。本文严格根据公司报告内容，分析其关键财务指标、业务亮点及投资影响。
核心财务指标及业绩对比表
| 指标 | 2026财年下半年 （截至2026年3月） |
2026财年上半年 （截至2025年9月） |
2025财年下半年 （截至2025年3月） |
同比变化 | 环比变化 |
|---|---|---|---|---|---|
| 收入（千新元） | 14,468 | 14,820 | 14,195 | +1.9% | -2.4% |
| 税后净（亏）/利润（千新元） | (531) | 35 | 87 | 不具意义* | 不具意义* |
| 每股收益EPS（分，基本） | 0.00 | 0.04 | 0.07 | 不具意义* | 不具意义* |
| 每股净资产（分） | 1.10（2026年3月） | – | 1.04（2025年3月） | +5.8% | – |
| 分红（每股） | 无 | 无 | 无 | – | – |
*不具意义：因处于净亏损，无法反映增长或下降。
历史表现与趋势
- 收入：2026财年收入同比增长5.9%至2,928.8万新元，三大业务板块均有增长。
- 盈利能力：归属于母公司的净利润从2025财年的60万新元降至20万新元，若剔除Ardennes业务相关一次性亏损和费用，调整后净利润为60万新元。
- 成本与费用：医疗耗材和员工费用随收入及团队扩张同步上升，其他运营费用增加主要因市场营销、租金和一次性资产处置损失。
- 每股收益与净资产：基本每股收益从0.10分降至0.04分，每股净资产略有提升。
特殊事项与资本运作
- Ardennes健康中心关闭：因业绩不佳于2026年2月关闭，相关一次性亏损和资产减值已计入。
- 并购：完成对PMG INT 2（更名为PMG RH）和Wellington Pte Ltd的100%收购，增加商誉140万新元，扩展初级诊所网络。
- 剥离与注销：两家休眠子公司（Venture Investment和Atlas Physiotherapy）已注销。VirtueMed 2%股权转让后已不再合并报表。
- 融资：2024年7月通过供股及认股权证发行融资138万新元，2026财年认股权证行权获得1.9万新元，新增银行授信400万新元以支持扩张及营运资金。
- 关联交易：与董事亲属控股公司签署租赁协议，支付租金25.1万新元，价格公允，其他关联交易金额较小。
分红政策
- 2026财年及上一财年均未宣布或建议派息，董事会认为应保留现金以支持营运及扩张计划。
管理层评论与展望
“本年度，集团关闭了表现欠佳的Ardennes体检中心，作为集团优化医疗网络、提升运营效率的战略举措之一。集团将继续投入并专注于医生和医疗人才的保留，这对维持集团收入增长起到关键作用……由于地缘政治紧张和通胀压力，集团对未来业务前景持谨慎态度，运营环境仍具挑战。”
整体语调务实审慎，强调持续投资医疗人才和网络扩张，但也警示宏观环境和成本压力风险。
前瞻性事件与风险
- 集团计划利用新增银行授信进一步扩展医疗网络，并探索收购机会。
- 管理层指出通胀、地缘政治等宏观风险，未来盈利增长或将受限。
结论与投资建议
总体评价：利文斯通医疗收入保持中速增长，资产结构稳定，但盈利能力因重组成本和营运费用上升而承压。集团战略聚焦于医疗网络整合与扩展，但宏观挑战和成本压力短期内将限制盈利提升空间。
- 如您已持有该股：建议继续持有。公司专注于长期增长和提升运营效率，资产负债表健康，但无分红且盈利增长缓慢，需耐心关注盈利改善及扩张成效。
- 如您未持有该股：建议观望。当前缺乏明显的股价上涨或分红催化剂，可待后续盈利改善或并购成效显现时再考虑介入。
免责声明：本分析仅基于公司公开报告，不构成投资建议。投资者应结合自身风险承受能力，咨询持牌理财顾问后再作决定。
